Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Breast cancer

Ret proto-oncogene (RET)

Studies in cell culture suggest inhibiting RET could be useful for treating aromatase inhibitor-resistant breast cancer. In cell culture and in human primary tumor samples, estrogen receptor-positive breast cancer cells treated with aromatase inhibitors had higher RET expression than estrogen receptor-negative controls. In cell culture models, a small molecule inhibitor of RET signaling decreased colony formation compared with growth factor- or hormone-treated controls. Next steps include testing combinations of RET inhibitors and aromatase inhibitors in xenograft models for breast cancer and developing more selective RET inhibitors.

SciBX 6(20); doi:10.1038/scibx.2013.485
Published online May 23, 2013

Unpatented; licensing status not applicable

Morandi, A. et al. Cancer Res.; published online May 6, 2013;
doi:10.1158/0008-5472.CAN-12-4265
Contact: Clare M. Isacke, The Institute of Cancer Research, London, U.K.
e-mail:
clare.isacke@icr.ac.uk